UBS: HUTCHMED Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than ExpectedAASTOCKS News·Nov 20, 2026 at 07:16 AMHCM-3.86%HAWG-1.50%
Sino Biopharmaceutical drops 5% in Hong Kong tradingMarket Movers·Nov 20, 2026 at 06:52 AM01177-4.85%
Citi Raises HUTCHMED TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick StatusAASTOCKS News·Nov 20, 2026 at 06:14 AMHCM-3.86%HAWG-1.50%
China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug TrialPUBT·Nov 19, 2026 at 12:09 PM00867-3.25%
Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing Share BuybackPUBT·Nov 19, 2026 at 09:05 AM02196-4.77%600196-1.98%
Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and ManageableAASTOCKS News·Nov 19, 2026 at 08:06 AMHCM-3.86%01093-4.58%
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia | HCM Stock NewsStockTitan·Nov 19, 2026 at 02:00 AMHCM-3.86%HAWG-1.50%
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics | HCM Stock NewsStockTitan·Nov 18, 2026 at 04:00 PMHCM-3.86%HAWG-1.50%
Shanghai Fosun Pharmaceutical Files HKEX Return Disclosing Share BuybackPUBT·Nov 18, 2026 at 09:30 AM02196-4.77%600196-1.98%